Abstract
Increasingly, patient models of disease are being utilized to facilitate precision medicine approaches through molecular characterization or direct chemotherapeutic testing. Organoids, 3-dimensional (3D) cultures of neoplastic cells derived from primary tumor specimens, represent an ideal platform for these types of studies because benchtop protocols previously developed for 2-dimensional cell lines can be adapted for use. These protocols include directly testing the survival of these organoid cultures when exposed to clinically relevant chemotherapeutic agents, a process we have called pharmacotyping. In this protocol, established tumor-derived organoid cultures are dissociated into single cells, plated in a 3D gel matrix, and exposed to pharmacologic agents. While our protocol has been developed for use with patient-derived pancreatic ductal adenocarcinoma organoids, with minor modifications to the dissociation and medium conditions, this protocol could be adapted for use with a wide range of organoid cultures. We further describe our standard ATP-based assay to determine cellular survival. This protocol can be scaled for use in high-throughput assays.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Howlader N, Noone A, Krapcho M et al. (2016) SEER cancer statistics review, 1975–2013. National Cancer Institute. http://seer.cancer.gov/csr/1975_2013/. Accessed July 2016
DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M et al (2013) Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (alliance) intergroup phase 2 trial. Ann Surg 258:422–429
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al (2013) Signatures of mutational processes in human cancer. Nature 500:415–421
Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF et al (2017) Real time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res 23:6094–6100. pii: clincanres.0899.2017
Witkiewicz AK, Balaji U, Eslinger C, McMillan E, Conway W, Posner B et al (2016) Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer. Cell Rep 16:2017–2031
Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V et al (2015) Organoid models of human and mouse ductal pancreatic cancer. Cell 160:324–338
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Burkhart, R.A., Baker, L.A., Tiriac, H. (2018). Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping. In: Wagner, B. (eds) Phenotypic Screening. Methods in Molecular Biology, vol 1787. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7847-2_19
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7847-2_19
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7846-5
Online ISBN: 978-1-4939-7847-2
eBook Packages: Springer Protocols